Drug Trial Radar · NCT06650852
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Oct 31, 2024
Primary completion
Sep 2028
Study completion Sep 2029
Sponsor
- Lead sponsor
- Brii Biosciences LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2, randomized, double-blind study will evaluate the clinical efficacy and safety of the combination therapy of BRII-179, BRII-835, plus PEG-IFNα compared to PEG-IFNα in adult participants with chronic HBV infection without cirrhosis receiving neucloes(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.
Conditions
- Chronic Hepatitis B Virus (HBV) Infection
Interventions
BRII-179Biological
BRII-179 will be given via intramuscular injection
BRII-835 (VIR-2218)Drug
BRII-835 will be given via subcutaneous injection
PEG-IFNαBiological
PEG-IFNα will be given via subcutaneous injection
Placebo of BRII-179Drug
Placebo of BRII-179 will be given via intramuscular injection
Placebo of BRII-835Drug
Placebo of BRII-835 will be given via subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage of participants achieving HBsAg seroclearance.Time frame: Up to 48 weeks
- Percentage of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).Time frame: Up to 96 weeks
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Investigative Site 86001
Beijing, Beijing Municipality, China · Recruiting
Investigative Site 86003
Beijing, Beijing Municipality, China · Recruiting
Investigative Site 86004
Beijing, Beijing Municipality, China · Recruiting
Investigative Site 86005
Beijing, Beijing Municipality, China · Recruiting
Investigative Site 86016
Beijing, Beijing Municipality, China · Recruiting
Investigative Site 86002
Guangzhou, Guangdong, China · Recruiting
Investigative Site 86013
Guangzhou, Guangdong, China · Recruiting
Investigative Site 86015
Shenzhen, Guangdong, China · Recruiting
Investigative Site 86006
Shanghai, Shanghai Municipality, China · Recruiting
Investigative Site 86007
Shanghai, Shanghai Municipality, China · Recruiting
Investigative Site 86010
Chengdu, Sichuan, China · Recruiting
Investigative Site 86011
Chengdu, Sichuan, China · Recruiting
Investigative Site 86012
Chengdu, Sichuan, China · Recruiting
Investigative Site 86009
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.